$MRNA Q1 2EPS $(3.07) beats $(3.55) Est.
Sales $167M beat $97.5M Est.

$167M in Spikevax sales, which includes $100M U.S. sales and $67M in international sales.
Cash, cash equivalents $12.2B

$REGN Q1 Adj EPS $9.55 misses $10.10 Est.
Sales $3.15B miss $3.22B Est.

Q1 U.S. net sales for EYLEA HD and EYLEA $1.40B.
Q1 revenues decreased 1% to $3.15B
New $3B share repurchase program authorized.

$PSTX and Astellas Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology. $ALPMY
Poseida will receive $50M upfront.

prnewswire.com/news-releases/…

$TSLA short sellers lose more than $5 billion in post-earnings rally.

finance.yahoo.com/news/tesla-sho…

$SRPT Q1 Adj EPS $0.73 beats $(0.07) Est.
Sales $413.4M beat $373.2M Est. 💥

$SRPT Q1 net product revenues $359.5M. ↑ 55% over the same quarter of the prior year
ELEVIDYS net revenues $134M.
Cash, cash equivalents $1.44B

$LLY 'could be on its way to becoming a $1 trillion market cap company' - Cantor.
PT raised to $885

'In recent months, there has been a lack of further progress toward the Committee's 2 percent inflation objective.' #FOMC

#FOMC Rate Decision Full Statement

federalreserve.gov/newsevents/pre…

$LPCN Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154.

Topline data late in Q2 with the goal of NDA submission by the end of Q4

$SLS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
globenewswire.com/news-release/2…

$ALRN Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
investors.aileronrx.com/news-releases/…

$YTEN 1-for-24 Reverse Split

$OCUL Q1 on May 7th.
The Company plans to host an Investor Day in NYC on June 13, in lieu of Q1 earnings conference call.

$MRK Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

$TGTX Q1 net revenue of $50.5M
Total revenue for Q1 $63.5M

Updating BRIUMVI U.S. net product revenue target to $270M to $290M (prior guidance of $220 to $260M)

$PFE Q1 Adj EPS $0.82 beats $0.54 Est.
Sales $14.9B beat $14.2B Est.

Revenue is ↓ 20% YoY though.
Current financial guidance does not anticipate any share repurchases in FY'24.